Tuberc Respir Dis.  2024 Apr;87(2):185-193. 10.4046/trd.2023.0093.

Association between Antacid Exposure and Risk of Interstitial Lung Diseases

• Bae S
• Loloci G
• Lee DY
• Jang HJ
• Jeong J
• Choi WI

• KMID: 2553777
• DOI: http://doi.org/10.4046/trd.2023.0093

Abstract

Background
The mechanisms leading to lung fibrosis are still under investigation. This study aimed to demonstrate whether antacids could prevent the development of interstitial lung disease (ILD).
Methods
This population-based longitudinal cohort study was conducted between January 2006 and December 2010 in South Korea. Eligible subjects were ≥40 years of age, exposed to proton pump inhibitors (PPI)±histamine-2 receptor antagonists (H-2 blockers) or H-2 blockers only, and had no history of ILD between 2004 and 2005. Exposure to antacids was defined as the administration of either PPI or H-2 receptor antagonists for >14 days, whereas underexposure was defined as antacid treatment administered for less than 14 days. Newly developed ILDs, including idiopathic pulmonary fibrosis (IPF), were counted during the 5-year observation period. The association between antacid exposure and ILD development was evaluated using adjusted Cox regression models with variables, such as age, sex, smoking history, and comorbidities.
Results
The incidence rates of ILD with/without antacid use were 43.2 and 33.8/100,000 person-years, respectively and those of IPF were 14.9 and 22.9/100,000 person-years, respectively. In multivariable analysis, exposure to antacid before the diagnosis of ILD was independently associated with a reduced development of ILD (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.45 to 0.71; p<0.001), while antacid exposure was not associated with development of IPF (HR, 0.88; 95% CI, 0.72 to 1.09; p=0.06).
Conclusion
Antacid exposure may be independently associated with a decreased risk of ILD development.

Keyword

Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis; Antacid Exposure; Incidence